EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA

This phase II trial is testing whether combining the chemotherapy drug temozolomide with the immunotherapy atezolizumab can help shrink tumors or slow the disease in people with advanced small cell lung cancer that has spread or returned. About 56 participants will receive the co…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy plus the immunotherapy drug atezolizumab. It compares continuing atezolizumab alone versus adding radiation therapy to the chest and any remaining tumors. The g…

This study tests whether adding lamivudine, an antiviral drug, to standard chemotherapy and immunotherapy can prevent or delay drug resistance in people with extensive-stage small cell lung cancer. About 28 adults will receive the combination treatment. The goal is to see if this…

This study tests a drug called tarlatamab in 39 people with extensive-stage small cell lung cancer, a fast-growing cancer with low survival rates. Tarlatamab works by helping the body's immune cells attack cancer cells. The main goal is to see if the drug can stop the cancer from…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This study tests whether using biomarker tests to personalize maintenance therapy can help control extensive-stage small cell lung cancer. About 900 participants will receive durvalumab alone or combined with other drugs based on their cancer subtype. The goal is to see if this t…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…